Sanofi India posts Q4 CY22 PAT at Rs. 130.9 Cr
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
The company has reported total income of Rs. 691.9 crores during the quarter ended December 31, 2022
More than 5 lakh patients availed the benefit of queue-less OPD registration using this service
Clinical studies are expected to start in Q2 2023.
Alkem has submitted a detailed corrective and preventive action (CAPA) plan to the regulator within the stipulated timelines.
Ayurveda is one of the most advanced sciences of its times
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Becomes the 1st diagnostics company in India to launch BD MAX MDR TB test
Subscribe To Our Newsletter & Stay Updated